Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. Papur › Ymchwil › Heb ei adolygu gan gymheiriaid
  2. Cyhoeddwyd

    Quantitative risk-benefit analysis

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  3. Cyhoeddwyd

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  4. Cyhoeddwyd

    Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

    Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  5. Cyhoeddwyd

    The all wales medicines strategy group: assessments and appraisals

    Hughes, D. & Hughes, D. A., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  6. Cyhoeddwyd

    The assessment, determinants & economics of medication compliance & persistence

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  7. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  8. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  9. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  10. Cyhoeddwyd

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  11. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  12. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  13. Cyhoeddwyd

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  14. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  15. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  16. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  17. Papur › Ymchwil › Adolygwyd gan gymheiriaid
  18. Cyhoeddwyd

    A Systematic Review of Patient Preferences for Subcutaneous Medications

    Ridyard, C., Dawoud, D. & Hughes, D., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapuradolygiad gan gymheiriaid

  19. Cyhoeddwyd

    Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

    Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Tach 2015.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapuradolygiad gan gymheiriaid

  20. Cyhoeddwyd

    Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation

    Ridyard, C. & Hughes, D., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapuradolygiad gan gymheiriaid

  21. Cyhoeddwyd
  22. Cyhoeddwyd

    Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

    Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Tach 2013.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapuradolygiad gan gymheiriaid

  23. Murlen › Ymchwil › Adolygwyd gan gymheiriaid
  24. Cyhoeddwyd

    Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

    Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Medi 2017.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  25. Cyhoeddwyd
  26. Cyhoeddwyd

    Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

    Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 Mai 2017, t. P265. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  27. Cyhoeddwyd

    Health Economics Analysis Plans: Where Are We Now?

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Tach 2016, t. A397. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  28. Cyhoeddwyd

    Health economics analysis plans: the current state of play

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 Mai 2017, t. P144. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  29. Cyhoeddwyd

    Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations

    Ridyard, C. & Hughes, D., 7 Mai 2017, t. P141. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  30. Crynodeb › Ymchwil › Adolygwyd gan gymheiriaid
  31. Cyhoeddwyd

    Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

    Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Medi 2017, t. 22-23.

    Allbwn ymchwil: Cyfraniad at gynhadleddCrynodebadolygiad gan gymheiriaid

  32. Arall › Ymchwil › Adolygwyd gan gymheiriaid
  33. Cyhoeddwyd

    Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

    Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

    Allbwn ymchwil: Cyfraniad at gynhadleddAralladolygiad gan gymheiriaid

  34. Adroddiad Comisiwn › Ymchwil › Heb ei adolygu gan gymheiriaid
  35. Cyhoeddwyd

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  36. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  37. Cyhoeddwyd
  38. Cyhoeddwyd
  39. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  40. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  41. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  42. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  43. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  44. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  45. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  46. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  47. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  48. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  49. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  50. Cyhoeddwyd
  51. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  52. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  53. Cyhoeddwyd
  54. Cyhoeddwyd
  55. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  56. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn